Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,476 questions · 1,535 findings · 101 reviews

No studies found 233 · 15.2%GRADE not reported 332 · 21.6%Very low 209 · 13.6%Low 343 · 22.3%Moderate 279 · 18.2%High 139 · 9.1%

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Surgery +/- radiotherapy + (adjuvant) chemotherapy vs Surgery +/- radiotherapy alone (observation or adjuvant radiotherapy only)

Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Surgery +/- radiotherapy + (adjuvant) chemotherapy led to lower disease-free survival, adjuvant concurrent chemoradiation vs… compared with surgery +/- radiotherapy alone (observation or adjuvant radiotherapy…; GRADE not reported.

1 finding from 1 review

Surgery +/- radiotherapy + (adjuvant) chemotherapy vs Surgery +/- radiotherapy alone (observation or adjuvant radiotherapy only)

Overall survival, adjuvant concomitant chemoradiotherapy vs post-surgery radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Surgery +/- radiotherapy + (adjuvant) chemotherapy probably leads to lower overall survival, adjuvant concurrent chemoradiation vs adjuvant… compared with surgery +/- radiotherapy alone (observation or adjuvant radiotherapy… (moderate certainty).

1 finding from 1 review

Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy

Time to bladder cancer recurrence (absolute effect size estimates based on recurrence rate at 12 months)

Single‐dose intravesical chemotherapy instillation may leads to lower time to bladder cancer recurrence (absolute effect size estimates… compared with placebo or observation after nephroureterectomy (low certainty).

1 finding from 1 review

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

Death (all causes) · women with locally advanced cervical cancer

Hysterectomy (radical) with neoadjuvant chemotherapy showed no clear difference in overall survival Median compared with chemoradiotherapy alone (moderate certainty).

1 finding from 1 review